2017 AOCC/APAGE共识:接受抗肿瘤坏死因子治疗的炎症性肠病患者结核感染的风险评估

2017-10-10 亚洲克罗恩病和结肠炎组织 J Gastroenterol Hepatol. 2017 Oct 10.

2017年10月,亚洲克罗恩病和结肠炎组织(AOCC)联合亚太地区胃肠病学协会(APAGE)共同发布了接受抗肿瘤坏死因子治疗的炎症性肠病患者结核感染的风险评估和管理共识。文章主要建议内容包接受抗肿瘤坏死因子治疗括结核感染的风险,开始抗肿瘤坏死因子治疗前潜伏或活动性结核病筛查,准备抗肿瘤坏死因子治疗晚期结核感染的管理,抗肿瘤坏死因子治疗期间监测,抗肿瘤坏死因子治疗后结核感染的管理。

中文标题:

2017 AOCC/APAGE共识:接受抗肿瘤坏死因子治疗的炎症性肠病患者结核感染的风险评估

英文标题:

Asian Organization for Crohn’s and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment Part 1: risk assessment

发布日期:

2017-10-10

简要介绍:

2017年10月,亚洲克罗恩病和结肠炎组织(AOCC)联合亚太地区胃肠病学协会(APAGE)共同发布了接受抗肿瘤坏死因子治疗的炎症性肠病患者结核感染的风险评估和管理共识。文章主要建议内容包接受抗肿瘤坏死因子治疗括结核感染的风险,开始抗肿瘤坏死因子治疗前潜伏或活动性结核病筛查,准备抗肿瘤坏死因子治疗晚期结核感染的管理,抗肿瘤坏死因子治疗期间监测,抗肿瘤坏死因子治疗后结核感染的管理。

拓展指南:炎症性肠病相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=2017 AOCC/APAGE共识:接受抗肿瘤坏死因子治疗的炎症性肠病患者结核感染的风险评估)] GetToolGuiderByIdResponse(projectId=1, id=ab8d41c0015100be, title=2017 AOCC/APAGE共识:接受抗肿瘤坏死因子治疗的炎症性肠病患者结核感染的风险评估, enTitle=Asian Organization for Crohn’s and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment Part 1: risk assessment, guiderFrom=J Gastroenterol Hepatol. 2017 Oct 10., authorId=null, author=, summary=2017年10月,亚洲克罗恩病和结肠炎组织(AOCC)联合亚太地区胃肠病学协会(APAGE)共同发布了接受抗肿瘤坏死因子治疗的炎症性肠病患者结核感染的风险评估和管理共识。文章主要建议内容包接受抗肿瘤坏死因子治疗括结核感染的风险,开始抗肿瘤坏死因子治疗前潜伏或活动性结核病筛查,准备抗肿瘤坏死因子治疗晚期结核感染的管理,抗肿瘤坏死因子治疗期间监测,抗肿瘤坏死因子治疗后结核感染的管理。 , cover=, journalId=null, articlesId=null, associationId=1534, associationName=亚洲克罗恩病和结肠炎组织, associationIntro=, copyright=0, guiderPublishedTime=Tue Oct 10 00:00:00 CST 2017, originalUrl=, linkOutUrl=, content=<P>2017年10月,亚洲克罗恩病和结肠炎组织(AOCC)联合亚太地区胃肠病学协会(APAGE)共同发布了接受抗肿瘤坏死因子治疗的炎症性肠病患者结核感染的风险评估和管理共识。文章主要建议内容包接受抗肿瘤坏死因子治疗括结核感染的风险,开始抗肿瘤坏死因子治疗前潜伏或活动性结核病筛查,准备抗肿瘤坏死因子治疗晚期结核感染的管理,抗肿瘤坏死因子治疗期间监测,抗肿瘤坏死因子治疗后结核感染的管理。 </P> <P>拓展指南:<STRONG>与<FONT color=red>炎症性肠病</FONT>相关指南:</STRONG><BR> <UL> <LI><A title="2017 共识声明:抗肿瘤坏死因子治疗炎症性肠病治疗药物监测" target=_blank href="http://www.medsci.cn/guideline/show_article.do?id=9ef291c001509341">2017 共识声明:抗肿瘤坏死因子治疗炎症性肠病治疗药物监测</A> <LI><A title=抗肿瘤坏死因子α单克隆抗体治疗炎症性肠病专家共识(2017) target=_blank href="http://www.medsci.cn/guideline/show_article.do?id=2dc9f1c0015030f6">抗肿瘤坏死因子α单克隆抗体治疗炎症性肠病专家共识(2017)</A> <LI><A title=建立全国通用的炎症性肠病诊治过程的关键性质量控制指标的共识意见 target=_blank href="http://www.medsci.cn/guideline/show_article.do?id=6c0a31c001a8e4da">建立全国通用的炎症性肠病诊治过程的关键性质量控制指标的共识意见</A> <LI><A title=炎症性肠病合并机会性感染专家共识意见 target=_blank href="http://www.medsci.cn/guideline/show_article.do?id=5ca8f1c001ae419c">炎症性肠病合并机会性感染专家共识意见</A> <LI><A title="2013 NICE诊断指南:炎症性肠病粪便钙卫蛋白诊断测试(DG.11)" target=_blank href="http://www.medsci.cn/guideline/show_article.do?id=a66e71c001a561cf">2013 NICE诊断指南:炎症性肠病粪便钙卫蛋白诊断测试(DG.11)</A> 更多信息请点击:<A target=_blank href="http://www.medsci.cn/guideline/list.do?q=%E7%82%8E%E7%97%87%E6%80%A7%E8%82%A0%E7%97%85">有关炎症性肠病更多指南</A></LI></UL> <P></P>, tagList=[TagDto(tagId=9498, tagName=抗肿瘤坏死因子), TagDto(tagId=1125, tagName=炎症性肠病), TagDto(tagId=13190, tagName=结核感染), TagDto(tagId=1115, tagName=风险评估)], categoryList=[CategoryDto(categoryId=4, categoryName=消化, tenant=100), CategoryDto(categoryId=9, categoryName=感染, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=4, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=5066, appHits=85, showAppHits=0, pcHits=3807, showPcHits=1547, likes=174, shares=1, comments=5, approvalStatus=1, publishedTime=Sat Oct 21 23:33:55 CST 2017, publishedTimeString=2017-10-10, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Sat Oct 21 23:33:55 CST 2017, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 18:50:31 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2017 AOCC/APAGE共识:接受抗肿瘤坏死因子治疗的炎症性肠病患者结核感染的风险评估)])
2017 AOCC/APAGE共识:接受抗肿瘤坏死因子治疗的炎症性肠病患者结核感染的风险评估
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=361066, encodeId=f09d3610667a, content=感谢分享。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=98062550206, createdName=天天作西, createdTime=Wed Feb 20 05:42:04 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361064, encodeId=4584361064a7, content=谢谢。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=98062550206, createdName=天天作西, createdTime=Wed Feb 20 05:41:54 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254979, encodeId=6a592549e9a1, content=谢谢.好好好好好好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Sun Oct 22 05:53:03 CST 2017, time=2017-10-22, status=1, ipAttribution=)]
    2019-02-20 天天作西

    感谢分享。

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=361066, encodeId=f09d3610667a, content=感谢分享。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=98062550206, createdName=天天作西, createdTime=Wed Feb 20 05:42:04 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361064, encodeId=4584361064a7, content=谢谢。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=98062550206, createdName=天天作西, createdTime=Wed Feb 20 05:41:54 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254979, encodeId=6a592549e9a1, content=谢谢.好好好好好好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Sun Oct 22 05:53:03 CST 2017, time=2017-10-22, status=1, ipAttribution=)]
    2019-02-20 天天作西

    谢谢。

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=361066, encodeId=f09d3610667a, content=感谢分享。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=98062550206, createdName=天天作西, createdTime=Wed Feb 20 05:42:04 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361064, encodeId=4584361064a7, content=谢谢。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=98062550206, createdName=天天作西, createdTime=Wed Feb 20 05:41:54 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254979, encodeId=6a592549e9a1, content=谢谢.好好好好好好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Sun Oct 22 05:53:03 CST 2017, time=2017-10-22, status=1, ipAttribution=)]
    2017-10-22 yjs木玉

    谢谢.好好好好好好

    0